116 related articles for article (PubMed ID: 27487085)
1. Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma.
Ikeda K; Kawamura Y; Kobayashi M; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Hepatol Res; 2017 Jun; 47(7):632-640. PubMed ID: 27487085
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma.
Seko Y; Ikeda K; Kawamura Y; Fukushima T; Hara T; Sezaki H; Hosaka T; Akuta N; Suzuki F; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Kumada H
Hepatol Res; 2013 Sep; 43(9):942-9. PubMed ID: 23301851
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma.
Okimoto K; Ogasawara S; Chiba T; Ooka Y; Oobu M; Azemoto R; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Yoshikawa M; Yokosuka O
Anticancer Res; 2013 Dec; 33(12):5603-9. PubMed ID: 24324105
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
5. Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin.
Handa T; Imai Y; Sugawara K; Chikayama T; Nakazawa M; Ando S; Hamaoka K; Inao M; Nakayama N; Mochida S
Hepatol Res; 2014 Oct; 44(11):1072-80. PubMed ID: 23957866
[TBL] [Abstract][Full Text] [Related]
6. Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma.
Yasui D; Murata S; Onozawa S; Mine T; Ueda T; Sugihara F; Kawamoto C; Uchida E; Kumita S
Biomed Res Int; 2014; 2014():359296. PubMed ID: 25276780
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Imai Y; Chikayama T; Nakazawa M; Watanabe K; Ando S; Mizuno Y; Yoshino K; Sugawara K; Hamaoka K; Fujimori K; Inao M; Nakayama N; Oka M; Nagoshi S; Mochida S
J Gastroenterol; 2012 Feb; 47(2):179-86. PubMed ID: 21976133
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma.
Arai H; Abe T; Takayama H; Toyoda M; Ueno T; Kakizaki S; Sato K
Hepatol Res; 2015 Jun; 45(6):663-6. PubMed ID: 25132539
[TBL] [Abstract][Full Text] [Related]
9. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: Short-term results.
Ogawa M; Takayasu K; Hirayama M; Miura T; Shiozawa K; Abe M; Matsumoto N; Nakagawara H; Ohshiro S; Yamamoto T; Tanaka N; Moriyama M; Mutou H; Yamamoto Y; Irie T
Hepatol Res; 2016 Mar; 46(3):E60-9. PubMed ID: 25974615
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma.
Ueda T; Murata S; Yasui D; Mine T; Kumita S
Hepatol Res; 2013 Oct; 43(10):1071-7. PubMed ID: 23905645
[TBL] [Abstract][Full Text] [Related]
12. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Tawada A; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Ogasawara S; Suzuki E; Kanai F; Yoshikawa M; Yokosuka O
Anticancer Res; 2015 Jan; 35(1):549-54. PubMed ID: 25550601
[TBL] [Abstract][Full Text] [Related]
14. Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma.
Ishikawa T; Abe S; Watanabe T; Nozawa Y; Sano T; Iwanaga A; Seki K; Honma T; Yoshida T
Mol Clin Oncol; 2016 Nov; 5(5):511-516. PubMed ID: 27882236
[TBL] [Abstract][Full Text] [Related]
15. Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules.
Kawamura Y; Ikeda K; Fujiyama S; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Arase Y; Kumada H
Hepatol Res; 2017 Mar; 47(4):338-346. PubMed ID: 27249401
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma.
Kubota K; Hidaka H; Nakazawa T; Okuwaki Y; Yamane K; Inoue T; Uojima H; Takada J; Tanaka Y; Shibuya A; Fujii K; Woodhams R; Matsunaga K; Kokubu S; Koizumi W
Hepatol Res; 2018 Feb; 48(3):E98-E106. PubMed ID: 28656607
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial.
Otsuji K; Takai K; Nishigaki Y; Shimizu S; Hayashi H; Imai K; Suzuki Y; Hanai T; Ideta T; Miyazaki T; Tomita E; Shimizu M; Moriwaki H
Hepatol Res; 2015 May; 45(5):514-22. PubMed ID: 24961745
[TBL] [Abstract][Full Text] [Related]
18. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience.
Kora S; Urakawa H; Mitsufuji T; Osame A; Higashihara H; Yoshimitsu K
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1023-9. PubMed ID: 23238851
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
Liu C; Sun L; Xu J; Zhao Y
World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
[TBL] [Abstract][Full Text] [Related]
20. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
